Aura Biosciences Files 8-K for Operations Update
Ticker: AURA · Form: 8-K · Filed: 2024-05-09T00:00:00.000Z
Sentiment: neutral
Topics: operations, financials, sec-filing
TL;DR
Aura Biosciences filed an 8-K on May 9th, updating investors on financials and operations.
AI Summary
Aura Biosciences, Inc. filed an 8-K on May 9, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signifies Aura Biosciences is providing an official update on its financial condition and operational results to the SEC, which is important for investors to monitor company performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of operational and financial information, not indicating any immediate adverse events.
Key Players & Entities
- Aura Biosciences, Inc. (company) — Registrant
- May 09, 2024 (date) — Date of earliest event reported
- 001-40971 (other) — Commission File Number
- 32-0271970 (other) — IRS Employer Identification No.
- 80 Guest Street, Boston, Massachusetts 02135 (address) — Principal Executive Offices
- 617 500-8864 (phone_number) — Registrant's Telephone Number
FAQ
What specific financial results are being reported by Aura Biosciences?
The provided text of the 8-K filing does not contain specific financial figures or details regarding the results of operations.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on Aura Biosciences, Inc.'s Results of Operations and Financial Condition, and to file Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on May 09, 2024.
What is Aura Biosciences, Inc.'s principal executive office address?
Aura Biosciences, Inc.'s principal executive office is located at 80 Guest Street, Boston, Massachusetts 02135.
What is Aura Biosciences, Inc.'s Commission File Number?
Aura Biosciences, Inc.'s Commission File Number is 001-40971.
Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-05-09 07:05:12
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share AURA The Nasdaq
Filing Documents
- aura-20240509.htm (8-K) — 41KB
- aura-ex99_1.htm (EX-99.1) — 164KB
- img28679202_0.jpg (GRAPHIC) — 3KB
- 0000950170-24-056252.txt ( ) — 336KB
- aura-20240509.xsd (EX-101.SCH) — 25KB
- aura-20240509_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 9, 2024, Aura Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. d) Exhibits. Exhibit No . Description 99.1 Press Release Dated May 9, 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aura Biosciences, Inc. Date: May 9, 2024 By: /s/ Julie Feder Julie Feder Chief Financial Officer